EU Commission proposes Critical Medicines Act to bolster supply of critical medicines

Mechanism

The CMA is layered on top of, not a replacement for, existing EU pharma legislation (Directive 2001/83 + Regulation 726/2004). Its four operational levers:

1. Strategic Project designation. Member-State-nominated or Commission-recognised projects for critical-medicine manufacturing — finished dosage forms or active pharmaceutical ingredients (APIs) — qualify for fast-tracked permitting, priority access to InvestEU + Horizon Europe funding, and defined state-aid leeway. Mirrors the Strategic Project pathway in the EU CRMA for critical raw materials.

2. Public-procurement preferences. Member-State authorities procuring critical medicines must consider non-price criteria that reward resilient supply chains (manufacturing-site geographic diversification, multi-source APIs, climate resilience, cybersecurity). For specifically defined "essentiality" categories the Act allows preference for EU-based production — the most contentious provision because it touches WTO non-discrimination commitments.

3. Collaborative cross-Member-State procurement. Aggregates demand across small national markets to make orphan-drug and pediatric-formulation manufacturing economically viable. Operationalised via the Health Emergency Preparedness and Response Authority (HERA) + the Critical Medicines Alliance.

4. International diversification + state-aid framework. Guidance on how Member-State subsidies for critical-medicine manufacturing can be granted without breaching state-aid prohibitions; partnership instruments for diversifying API sourcing away from concentrated third-country dependencies.

Why severity 3

• Proposal stage, not enacted. As of filing (2026-04),

Commission proposal is published, EP rapporteur appointed, Council position adopted 2 December 2025. Trilogue is the next political step before adoption + entry into force. Severity may be revised to 4 once enacted.

• Positive-incentive lever, not coercive. Unlike export

controls or tariffs, the CMA pulls capacity into the EU via funding + procurement preference rather than restricting flows. Industrial-policy lever, not trade-restrictive.

• Material once binding. EU pharma manufacturing capacity

is materially constrained on APIs (estimates: ~70-80% of generic APIs sourced from China + India). The Act's enacted form would shift €-billions of procurement and investment flow over a multi-year horizon.

Downstream implications

• EU pharma manufacturers with European API capacity (Sanofi,

Novartis, Recipharm, Fareva, Siegfried) gain optionality on Strategic Project status + procurement preference. NPV-positive for European-based fill-finish + API expansion projects.

• Indian + Chinese API manufacturers (Aurobindo, Dr. Reddy's,

Sun Pharma, several Chinese state-linked producers) face potential demand-side reshoring pressure on the Union List basket. Net effect depends on price elasticity and on whether EU-based capacity can scale within the implementation horizon.

• US pharma supply chains are not directly affected but

the CMA precedent — combined with the 2025 Trump MFN drug-pricing EO (filed: 2025-05-12-us-trump-mfn-drug-pricing-eo14273) — shows pharma joining semis + critical minerals as a sector where Western governments are layering supply-chain industrial policy on top of existing market regulation.

• Cross-references. Fits the

/actions/themes/western-industrial-policy-stack theme: same positive-funding + procurement-preference logic as the IRA's §30D / §45X for batteries + critical minerals, and the EU CRMA for raw materials. Pharma is the third major axis where the Western IP stack is now operating.

Sourcing note

Five sources verified — four EU-side primaries (Commission press release IP/25/733, Q&A QANDA/25/734, DG SANTE landing page, Council 2025-12-02 position) plus a Euronews secondary dated to the proposal date. Primary URLs spot-verified via WebFetch; the press-corner pages are JS-rendered so direct content extraction is blocked from this VPS, but the DG SANTE page rendered successfully and confirmed the March 2025 proposal date + main provisions. The 11 March 2025 exact date was confirmed by multiple secondary sources triangulating to the same day.

Open questions

• Trilogue outcome timing. EP committee vote, trilogue

conclusion, and final adoption schedule — likely 2026 if political alignment holds. The Council 2025-12-02 position is the most recent procedural milestone.

• Buy-European procurement scope. The exact list of

"essentiality" categories triggering EU-preference clauses is a key political negotiation — narrow scope = light industrial impact; broad scope = WTO friction risk.

• Funding envelope. The proposal references existing EU

funding instruments (InvestEU, Horizon Europe) without creating new dedicated budget lines. The size of capacity shift depends on how Member States deploy state-aid headroom.

• Severity upgrade trigger. Re-score to 4 once the Act is

adopted by Parliament + Council and enters into force.